Cardium Therapeutics (CXM)

So,hier gibt es keinen Cardium Thread mehr auf Ariva,deshalb mach ich einen auf,neue WKN ist A1W2PN ,gleich mal ganz aktuell von heute:

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced its support of Life Insurance Awareness Month.  The campaign, taking place during September, is sponsored by the Life and Health Insurance Foundation for Education (LIFE).  LIFE is dedicated to helping individuals take personal financial responsibility through the ownership of life insurance and other related insurance, including disability and long-term care insurance, to ensure their loved ones are financially protected.  

(Logo: photos.prnewswire.com/prnh/20130919/LA82808LOGO)

While life insurance rates for the traditional insurable population are now more affordable than ever, the percentage of U.S. households owning individual life insurance has steadily declined over the past 25 years—from 62 percent in 1985 to an all-time 50-year low of 44 percent in 2010.  However, for cancer patients who really do "need life insurance," their hands often are tied. Life insurance typically only becomes an option after five years of being cancer free.  Even then, it can be an uphill battle depending on the type, stage, grade of the cancer, and the treatment plan.

To address this problem, LifeAgain recently launched its BlueMetric™ Select term life insurance program for men with active localized prostate cancer.  The BlueMetric Select program was developed based on LifeAgain's Advanced Medical Data Analytics Platform Technology (ADAPT™).  Prostate cancer is one of the most prevalent forms of cancer in the United States. Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional underwriting standards.  LifeAgain's BlueMetric Select program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About The Life and Health Insurance Foundation for Education

The Life and Health Insurance Foundation for Education (LIFE) is a nonprofit organization dedicated to helping consumers make smart insurance decisions to safeguard their families' financial futures. LIFE's mission is to educate the public about the essential role of life and health insurance in sound financial and retirement planning and the value added by insurance agents and other financial advisors. Visit www.lifehappens.org.

About LifeAgain

LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of "survivable risk" term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain's initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com

MFG
Chali

Endlich ist es Cardium gelungen Excellagen zu vermarkten:

Excellagen ist ein Wundheilungspräparat, dass in Gelform aufgetragen wird.
Die Studienergebnisse haben eine bis 30% schnellere Wundheilung als
bei der gegenwärtigen Standardanwendung (Regranex Gel) aufgezeigt.
Der Markt für die Anwendung an Fußgeschwüren von Diabetikern wird auf bis zu
2 Mrd Dollar geschätzt. Entsprechend groß ist das Potenzial dieser kleinen Firma.
Nach erfolgter Zulassung wird Excellagen wohl auslizensiert und könnte
schätzungsweise alleine 300 Mio an Upfront Payments einbringen. Wohlgemerkt
ist CXM mit 6 Mio Dollar bewertet. Wie stichhaltig diese Schätzungen allerdings sind
überlasse ich jedem einzelnen selbst zu beurteilen

Chalifmann

SAN DIEGO, Aug. 7, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen® advanced wound care product in Germany and Switzerland.  Kasiak Holdings is focused on developing stem cell-based therapeutics for the treatment of diabetic foot ulcers.  Kasiak Holdings is affiliated with Kasiak Research, which is an operating unit of India-based Bharat Serums and Vaccines, that develops and manufactures specialized biological, pharmaceutical and biotechnology products.  

(Logo: photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Cardium's FDA-cleared Excellagen is an aseptically-manufactured, quaternary fibrillar Type I bovine collagen homogenate that is configured into a staggered array of three-dimensional, triple helical, telopeptide-deleted, tropocollagen molecules.  This linear array forms a flowable, biocompatible and bioactive structural matrix that can promote chemotaxis, cellular adhesion, migration and proliferation to stimulate tissue formation. The Excellagen homogenate represents a new product delivery platform that allows for the potential development of a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media.

About Excellagen
Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen's FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen's unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen as part of Cardium's physician sampling, patient outreach and market "seeding" programs.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium's Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen's potential utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at www.excellagen.com/surgical-wounds.html.

MFG
Chali

Hm, der Kurs bröckelt aber nun unter geringen Umsätzen stetig ab. Wann lohnt denn hier ein Einstieg?  

Sag mal,bist du in Tesla wieder drin ? Meiner Meinung nach lohnt ein einstieg in Cardium gerade jetzt,auch wenn es momentan etwas bröckelt ! Übrigens,hast du im Organovo Thread den neusten Bericht gelesen ? Man ist nun schon soweit menschliche Organe in Miniformat zu drucken,und es sei nur noch eine Frage der Zeit,bis Originalgrösse möglich ist ! Wichtig für Cardium wäre die 1 dollar Marke kurzfristig ,damit es keine Listing Probs gibt,ich denke das klappt aber !

MFG
Chali

Nein, leider nicht mehr, hatte mich mit einem moderaten Gewinn verabschiedet. Nun jedoch all-time-high bei 180 USD, grrr.......

Cardium müsste sich verhundertfachen,um genauso teuer zu sein wie INO oder ONVO !
Das Potential ist meiner Meinung nach klar vorhanden,also ich bleib dabei !

Tesla doppelt so teuer wie Porsche und fast halb so teuer wie Daimler,das kann nicht mehr lange gut gehen,also mach dir nix draus und ärgere dich nicht ! Ich hab übrigens vor Cardium weiter aufzustocken,sobald Kohle da ist,die Aktie ist im Moment total unter Radar ......

Nüchtern betrachtet sieht es schon übel aus um die company,die Aktie hat sich seit 2009 gehundertstelt und man ist fast pleite mit noch 600.000 Dollar Cash. Ich habe deshalb meine Position geschlossen und mit 6% Verlust verkauft,iss mir zu heiss :

...hättest Du noch ein bisschen gewartet, hättest Du heute mit Gewinn verkaufen können.

Plus 13 %! Wie d´es machst, isses verkehrt.

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.
Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead r

MFG
Chali

mal einer sagen,ob hier nur die kurzfristigen zocker und Trader eingestiegen sind,oder ob das hier ein nachhaltiger fetter Rebound wird ?????? Ich hatte die Aktie im Verdacht insolvenzgefährdet zu sein und bin deshalb vorsichtshalber ausgestiegen,wer kenn sich mit den Zahlen besser aus als ich ?

Hi Chali, ich kann Dir da leider auch nichts zu sagen.

Bei iHub sind die Meinungen(wie immer) unterschiedlich. Vielleicht hilft Dir ein Blick hinein.

Gruß

investorshub.advfn.com/Cardium-Therapeutics-Inc-CXM-16154/  

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.

Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead resistance levels at $1.35.

www.thestreet.com/story/12051324/4/...10-making-big-moves.html

IHUB ist doch der letzte Schwachzockerladen,die Meinungen dort sind doch nicht brauchbar: Diese Deppen haben STOA gemeinschaftlich in den Himmel gelobt mit 10.000% plus,seitdem hat sich die Aktie gezehntelt !!! Ja ? Alles klar ? Jetzt weisst du wie brauchbar IHUB ist !

P.S. Den Street artikel kenn ich schion,siehe #11

... diskutiert. Manche Forenteilnehmer vermuten Großes, andere eher das Schlimmste. Jedenfalls tobt es dort ziemlich. Gut, das ist in Yahoo Finance Foren oft so, aber ich wüsste gern mal, wie ihr die Lage seht.

Ein Blick auf Cardium lohnt sich. Der 5-Jahres-Chart zeigt zwar nach unten, ein Rebound könnte aber bevorstehen. Der Kurs ist schon ganz schön in den Keller gerutscht.
Eine positive Meldung und es kann schnell mal 50% nach oben gehen...

Erstmalig sind die Umsätze bei CXM ins laufen gekommen bei knapp 2 mio,das kann aber noch deutlich mehr werden,denn Excellagen ist jetzt verparnert ! Ich würde folgende Strategie fahren: Wenn du mindestens 1000 Stück im Depot hast und es kommt zum Hype,dann würde ich im Bereich 2,50 - 3 dollar verkaufen.Das volumen ist nach wie vor sehr hoch und du gehst auf Nummer sicher,denn die finanzielle situation bei CXM scheint angespannt,es muss frisches Geld her. Von der Pipeline her ist CXM allerdings vom Feinsten ......

MFG
Chali

Was hier auffällt, ist die starke Abhängigkeit von den Cardium To Go Brands - 92% in Q1
und dass insgesamt noch rote Zahlen geschrieben werden.

Die pipeline, die Du ansprichst, wie sieht die eigentlich aus, Chalif?

For the three months ended March 31, 2013, the Company reported a lower net loss of $2.2 million, or $(0.02) per share, when compared to a net loss of $2.6 million, or $(0.02) per share for the three months ended March 31, 2012.  The decrease in net loss was due to cost reductions and increased sales revenue.  
Product sales for the three months ended March 31, 2013 totaled $599,000, compared to $20,000 for the same period in 2012. The increase in sales during the first quarter 2013 reflects sales from Cardium's To Go Brands health science-based operating unit (representing approximately 92% of total product sales) and sales of Cardium's Excellagen advanced wound care product (8% of total product sales).  

For the three months ended June 30, 2013, the Company reported a net loss of $2.1 million, or $(0.37) per share, when compared to a net loss of $1.9 million, or $(0.31) per share for the three months ended June 30, 2012.
Product sales for the three months ended June 30, 2013 totaled $585,000, compared to $13,000 for the same period in 2012. Product sales for the six months ended June 30, 2013 were $1.2 million, compared to $34,000 for the six months ended June 30, 2012.  The increase in product sales was comprised of sales from the Company's To Go Brands health sciences business, which Cardium acquired in late September 2012.  

die Zahlenjobs bei CRME und CXM. OK,du bist neu in biotech,aber die Zahlen interessieren hier bei CRME im Moment wirklich keinen,das ist bei biotech oft so ! Vor 3 Jahren,als Merck noch beteiligt war,stand CRME bei 60 Dollar und geändert hat sich eigentlich nichts,ausser das Merck nicht mehr dabei ist,ich werde unter 40 Dollar meine CRME nicht hergeben !!

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.

Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead resistance levels at $1.35.
Quelle: www.thestreet.com/story/12051324/4/...10-making-big-moves.html

So gesehen, sieht es ganz gut aus. Denn wir notieren ja klar über 1,00 USD

CXM hat im moment kein Geld,um die Pipline voranzutreiben und weiterzuentwickeln. Am interessantesten finde ich Generx in Phase-3. Das DNA Produkt zielt darauf ab,die Bypass Operationen abzulösen,ein Herzmedikament,das der Knaller schlechthin werden könnte. KÖNNTE !

... doch auch nicht. Denn wenn uns nur die "medizin-wissenschaftliche" pipeline bleibt, dann sind wir Non-Docs doch komplett außen vor. Mir gefällt bei CXM immerhin, dass sie ihre Pläne aus dem Abschlussbericht 2012 sehr schön verwirklicht haben. Eigentlich sollte sich allmählich auch wirtschaftlich einges tun. Und wenn das absehbar wird, dann kommt auch der Kurs aus'm Kreuz.

"Value in a biotechnology company's pipeline is not seen in current price per share but rather in projected value of the biotechnology company's intellectual property."

Das ist es, was Du meinst. Nicht wahr, Chalif

diese aussgae kann ich nicht nachvollziehen,denn dann müsste CXM mindestens 10 oder 100 mal so hoch stehen ......

... wie die Geschäfte laufen. Zahlen ;-)

Sollte man meinen ! Aber wenn ich Celldex mit 3 MRD sehe bei 9 Mio Umsatz oder Acadia Pharma mit 2,6 MRD noch ohne Zulassung,dann könnte ich daran zweifeln ! Langfristig entscheiden die Zahlen aber immer .....

CXM hätte die durchzugkraft noch nicht,aber in der letzten Handelsminute auf 1,12  Dollar hoch,damit steigen die Chancen zumindest auf einen kurzfristigen Hype ......

MFG
Chali

... geworfen. Bin gespannt, ob heute noch mal aufgeholt wird.  

Charts in biotech als den von CXM,schaut euch mal Oxygene (OXGN) an,ob da wohl ein fetter Rebound ansteht ?

Halten oder war's das? Was meinst Du, Chalif?

Moin mein Froind !

Meiner Meinung nach CXM abstossen,da zu unsicher und CRME aufstocken,da sehe ich eine goldene Zukunft ! Musst du aber selber wissen,du könntest auch einen Zwischenzock mit TTNP starten,das ding steigt erwartungsgemäss unter hohem Volumen bis zum Zulassungstermin mitte November .....

MFG
Chali

..... und bin wieder dabei !!!!

Cardium Reports On Advancement Of Generx And Excellagen Biologic Products And Corporate Developments
Clinical and Preclinical Results Have Implications for Use of Generx as a Non-Surgical Gene Therapy for Coronary Artery Disease, and Excellagen to Potentiate Stem Cell Therapies
PR Newswire
Cardium Therapeutics December 31, 2013 9:00 AM

SAN DIEGO, Dec. 31, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today reported on advancements of the Company's two key biologics products, its Generx® candidate for the potential treatment of coronary artery disease, and its Excellagen® advanced wound care product. The Company also provided an update on corporate developments including its exchange listing and strategic focus on the commercialization of its two lead biotechnology products and their potential follow-on products, each as discussed further below.

(Logo: photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

With regard to the Generx® product candidate for coronary artery disease, the Company has received encouraging initial findings from its clinical Phase 3 registration study that is evaluating Generx in patients with myocardial ischemia due to arteriosclerosis, the most common form of coronary artery disease and a major contributor to cardiovascular deaths and morbidity throughout the developing world.  The Aspire trial is a randomized, multi-center study with two parallel arms, and is being conducted at leading medical centers in Moscow and Novosibirsk to supplement previously-obtained data in other countries including the United States. Preliminary clinical data from the initial phase of the current study suggests that a one-time non-surgical administration of Generx can induce substantial improvements in cardiac blood flow or "myocardial perfusion" as measured quantitatively using SPECT imaging (Single-photon emission computed tomography). SPECT imaging results, which are the primary efficacy endpoint of the Aspire study, are being processed and reviewed by one of the world's leading centers involved in cardiac imaging and analysis, Cedars-Sinai Nuclear Cardiology Medical Center in Los Angeles. They are used to quantitatively measure the sufficiency of blood flow within the heart muscle under stress, and are considered to be a key prognostic indicator for the progression and risks associated with coronary artery disease. These findings are consistent with and further supportive of results observed in the Generx AGENT 2 clinical study that was conducted by Schering AG, from which Cardium obtained the product rights prior to Schering's acquisition by Bayer Healthcare. The Aspire clinical study has been designed to integrate new proprietary delivery techniques based on discoveries by Cardium researchers and to build upon findings from the AGENT clinical studies in the U.S. and Europe. The successful completion of the AGENT 2 clinical study served as the basis for Schering's acquisition of Collateral Therapeutics, a predecessor-in-interest of Cardium.

With these encouraging clinical results for its Generx biologic candidate having the potential to treat coronary artery disease, the Company intends to develop a plan to accelerate the Aspire study, and believes it will be in a position to provide an interim analysis in the first half of 2014.

With regard to its Excellagen® advanced wound care product, the Company has received positive findings from a European study that evaluated the role of Excellagen in a diabetic wound model, with and without stem cells. The results demonstrated that Excellagen had significant independent potential for wound healing, and also showed that Excellagen is capable of potentiating the effects of stem cells. The study was conducted by researchers led by Professor Timothy O'Brien at the National University of Ireland in Galway and Orbsen Therapeutics Ltd., and evaluated the medical utility of Excellagen as a delivery agent for Orbsen's proprietary human mesenchymal stem cells (MSC) for the potential treatment of diabetic wounds.  The research was sponsored by the European-funded ReddStar initiative. The study showed that Excellagen alone (in a control arm) had significant wound healing capability – confirming and extending results observed regarding the use of Excellagen for the treatment of diabetic wounds. In addition, microscopic and biological analyses demonstrated that human MSCs integrated well into Excellagen's three-dimensioned fibrillar scaffold, with the stem cells retaining positive biological activities and exhibiting increased wound healing potential in the presence of Excellagen. Cardium expects that a manuscript providing the details of these important new research findings will be submitted for publication in a peer-reviewed journal in 2014. The findings with human MSCs also open possibilities for the use of Excellagen in combination with stem cells for advanced wound healing applications, and potentially other applications in the emerging stem cell field.

Effective January 1, 2014, Excellagen will also be covered by a unique Q code product reimbursement designation as a "skin substitute" for the treatment of diabetic foot ulcers and a broad array of other wounds product by the U.S. Centers for Medicare and Medicaid Services (CMS).  Cardium further reported that based on current status regarding a planned CE mark for Excellagen, all information requested has been provided to the notified body, BSI, and the Company believes this process should lead to CE mark certification for its FDA-cleared advanced wound care product, a key step in enabling commercialization in Europe.

Cardium also reported on other corporate developments. The Company has completed the sale of its To Go Brands® business, which was acquired by Healthy Brands Collective® in an asset sale in exchange for a preferred equity stake in Healthy Brands. Healthy Brands' portfolio includes ten independent brand product platforms including Cell-nique®, Cherrybrook Kitchen®, Yumnuts®, Funky Monkey®, Lisa's Kitchen®, Living Harvest/Tempt®, Bites of Bliss®, High Country® probiota kombucha drinks and Organics European Gourmet Bakery™ (Dr. Oetker) natural and organic baking mixes.  Healthy Brands is a private company that expects to make additional brand acquisitions and has previously reported plans to move forward as a public company as its business advances through internal growth and by further acquisition. At an appropriate time, Cardium may consider the distribution or other monetization of its equity interests in Healthy Brands. For more information visit www.healthybrandscollective.com. Cardium, through its health sciences unit, retains the trademarks and technology relating to the MedPodium Nutra-apps and nutraceutical product line, and will retain its investment interest in SourceOne, a nutraceutical and health sciences ingredient supplier.

The Company also provided an update on its exchange listing, which it has reported on recently and over the last several quarters. As part of its restructuring and cost containment efforts designed to enable a strategic focus on its key biological products, Cardium reported that it will elect to have its common stock listed on the OTC exchange, an alternative regulated quotation service that provides electronic quotes, sale prices and volume information in over-the-counter equity securities. The Company's common stock traded on the OTC prior to the Company's election to list its shares on the American Stock Exchange, now NYSE MKT. Since stocks on the OTC electronic exchange trade using a 4-letter symbol, the Company's ticker symbol will be adjusted in connection with the new listing, which will be reported shortly. Shareholders will not be required to exchange any shares and the Company expects electronic trading to be available without any material disruption.

About Excellagen

Excellagen is a sterile, syringe-based, professional-use, physiologically formulated homogenate of purified bovine dermal collagen (Type I) in its native, 3-dimensional fibrillar configuration, providing a structural scaffold for cellular infiltration and wound granulation. Excellagen can activate platelets, triggering release of essential growth factors and is believed to function as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue. Excellagen's FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen's unique fibrillar collagen formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at one-week intervals.  For more information, visit www.excellagen.com.

About Generx

Generx (Ad5FGF-4) is a disease-modifying regenerative medicine biologic that is being developed to offer a one-time, non-surgical option for the treatment of myocardial ischemia in patients with stable angina due to coronary artery disease, who might otherwise require surgical and mechanical interventions, such as coronary artery by-pass surgery or balloon angioplasty and stents.  Similar to surgical/mechanical revascularization approaches, the goal of Cardium's Generx product candidate is to improve blood flow to the heart muscle – but to do so non-surgically, following a single administration from a standard balloon angioplasty catheter.  The ASPIRE Phase 3 registration is currently being conducted at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with cardiac microvascular insufficiency  due to myocardial ischemia as a result of advancing coronary artery disease. For additional information about Generx and the ASPIRE clinical study, please visit www.cardiumthx.com/generx.html.

About Cardium        

Cardium is a health sciences and biotechnology regenerative medicine company. Cardium has three business units: (1) Angionetic Therapeutics™, focused on the late-stage clinical development of Generx®, an angiogenic gene therapy product candidate for the treatment for cardiac microvascular insufficiency due to advancing coronary artery disease; (2) Activation Therapeutics™, a regenerative medicine wound healing technology and commercialization platform, that includes Excellagen®, an FDA-cleared advanced wound care product (www.excellagen.com); and (3) LifeAgain® Insurance Solutions, an advanced medical data analytics platform that supports the Company's BlueMetric Select term life insurance program, the only program currently available for men with active localized prostate cancer (www.lifeagain.com). For more information, visit www.cardiumthx.com.

MFG
Chali

bist Du hier eigentlich noch investiert ?

Ich überlege aufzustocken.

Deine Meinung ?

Bin auch in Cardiome drin.

gute Idee von dir ! Ist zwar in Deutschland nicht mehr handelbar,aber ich würde es genauso machen !

MFG
Chali